Skip to content

IEMbase 0049: SLC1A1-related dicarboxylic aminoaciduria

Scope

Field Value
IEMbase ID 49
Nosology 1.11.07.01
Gene SLC1A1
External IDs OMIM:222730
Generated mapping UNMAPPED
Candidate DisMech targets None
Review date 2026-07-07

IEMbase phenotype signal

IEMbase represents this as autosomal recessive SLC1A1-related dicarboxylic aminoaciduria. The biochemical signature is increased urinary aspartic acid and markedly increased urinary glutamic acid across all recorded ages. Plasma glucose is listed as low-to-normal only in the neonatal and infancy columns.

Clinical features are possible rather than defining: psychotic behavior, intellectual disability, and urolithiasis. IEMbase lists no treatments.

DisMech phenotype coverage

There is no local DisMech entry for SLC1A1-related dicarboxylic aminoaciduria. The local cystinuria and Hartnup entries are nearby amino-acid transport disorders, but neither is a valid target.

Cystinuria.yaml models cystine and dibasic amino acid transport involving SLC3A1/SLC7A9. Hartnup_Disease.yaml models neutral amino acid transport involving SLC6A19/B0AT1. IEMbase ID 49 is a dicarboxylic aminoaciduria with glutamate/aspartate urinary loss and SLC1A1.

Concordance and completeness

Judgement: true unmapped record. No current local disorder captures the SLC1A1 dicarboxylic amino-acid transporter phenotype.

The potential mistake to avoid is classifying this by the broad aminoaciduria label alone. The class of amino acid substrate is the key discriminator: dicarboxylic amino acids for SLC1A1, neutral amino acids for Hartnup, and cystine/dibasic amino acids for cystinuria.

Curation actions

  • Keep the record unmapped.
  • Do not map to Hartnup disease or cystinuria.
  • If curated later, use SLC1A1, urinary glutamic/aspartic acid excess, and the possible neuropsychiatric/urolithiasis features as the starting scope.